JT
Therapeutic Areas
Edgewise Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| EDG-5506 | Becker Muscular Dystrophy (BMD) | Phase 2/3 |
Leadership Team at Edgewise Therapeutics
KK
Kevin Koch, Ph.D.
President, CEO & Founder
JS
Joel Schneider, Ph.D.
COO & CFO
MB
Marc Belsky, J.D.
Chief Legal Officer & Corporate Secretary
AR
Alan Russell, Ph.D.
Chief Scientific Officer
SD
Simon Dagenais, Ph.D.
SVP, Development & Head of Clinical Development